Revenue View details
RMB million
163.427
YoY +21.6%
Source · p. 29FINANCIAL DATA · HKEX 01609
Financial & business data
FY2023–2025 and H1 2026. Figures, comparisons and the source behind each value.
H1 2026
Gross profit View details
RMB million
121.296
YoY +21.8%
Source · p. 29Profit attributable to owners of the parent View details
RMB million
27.402
YoY -26.1%
Source · p. 29Net cash flows from/(used in) operating activities View details
RMB million
-11.682
YoY Non-positive base or sign change; no growth rate
Source · p. 33Comparative period: H1 2025
All figures & definitions01 / PERFORMANCE
Performance over time
No figures are available for this comparison.
Annual and half-year figures are shown separately. Select a value to view its source.
02 / REVENUE MIX
Revenue composition
H1 2026
Revenue by product category
Product revenue categories, not multiple reportable operating segments. The financial statements identify one reportable operating segment: sale of sports medicine products. Others mainly comprises surgical utility carts and regenerative repair products for joint soft tissues.
RMB million · share of revenue
No breakdown disclosed for this period.
Source · p. 39Revenue by customer location
Revenue geography is based on customer locations; the prospectus financial review further describes distributors’ principal places of business. This does not identify the location of end hospitals or final use.
RMB million · share of revenue
No breakdown disclosed for this period.
Source · p. 3903 / DATA & DEFINITIONSAll financial figures
Amounts in RMB million, shown to three decimal places; ratios are labelled %. H1 2025 is the comparative period. Select a value to view the original disclosure.
| Metric / unit | FY2023 | FY2024 | FY2025 | H1 2025Comparative | H1 2026 |
|---|---|---|---|---|---|
| RevenueRMB millionConsolidated Group revenue from contracts with customers. | 238.542 | 327.119 | 402.751 | 134.378 | 163.427 |
| Cost of salesRMB millionCost of sales in the profit or loss statement, retaining the reported negative sign. | -61.234 | -99.524 | -104.132 | -34.791 | -42.131 |
| Gross profitRMB millionReported consolidated gross profit; revenue plus the signed cost of sales. | 177.308 | 227.595 | 298.619 | 99.587 | 121.296 |
| Other income and gainsRMB millionOther income and gains reported in the consolidated profit or loss statement. | 14.834 | 10.097 | 22.728 | 6.982 | 9.334 |
| Selling and distribution expensesRMB millionProfit or loss expense, retaining the reported negative sign. | -66.108 | -69.628 | -80.570 | -33.253 | -42.379 |
| Administrative expensesRMB millionAdministrative expenses, retaining the reported negative sign; listing expenses have not been excluded. | -26.165 | -22.768 | -36.706 | -9.928 | -32.729 |
| Research and development expensesRMB millionResearch and development expenses recognised in profit or loss, retaining the reported negative sign; not a measure of all R&D cash spending. | -35.024 | -37.252 | -47.503 | -21.144 | -23.743 |
| Profit before taxRMB millionProfit before tax in the consolidated profit or loss statement. | 64.322 | 107.568 | 154.168 | 41.956 | 30.124 |
| Income tax expenseRMB millionIncome tax expense in profit or loss, retaining the reported negative sign; not cash tax paid. | -7.210 | -12.179 | -17.198 | -4.865 | -2.722 |
| Profit attributable to owners of the parentRMB millionReported profit attributable to owners of the parent; equal to profit for the year/period in all periods shown, without non-IFRS adjustments. | 57.112 | 95.389 | 136.970 | 37.091 | 27.402 |
| Net cash flows from/(used in) operating activitiesRMB millionNet operating cash flows as reported, including interest received and income taxes paid classified in this section; negative values indicate a net outflow. | 79.856 | 94.515 | 157.116 | 22.061 | -11.682 |
| Net cash flows from/(used in) investing activitiesRMB millionNet investing cash flows as reported; negative values indicate a net outflow. This is not capital expenditure. | -21.168 | -371.252 | -120.561 | 55.704 | 75.173 |
| Net cash flows from/(used in) financing activitiesRMB millionNet financing cash flows as reported; negative values indicate a net outflow. | 24.594 | 10.133 | -9.354 | -0.533 | 638.142 |
| Cash and cash equivalents at period endRMB millionCash and cash equivalents at period end; excludes separately classified deposits over three months, certificates of deposit and financial assets at fair value. | 356.370 | 89.968 | 116.846 | 167.141 | 819.640 |
| Total assets at period endRMB millionConsolidated Group total assets at period end. The selected interim report does not present 30 June 2025; the 31 December 2025 figure is not substituted. | 451.278 | 617.334 | 764.081 | — | 1,433.160 |
| Total equity at period endRMB millionConsolidated Group total equity at period end. | 374.768 | 471.240 | 609.417 | — | 1,302.081 |
| Inventories at period endRMB millionNet carrying amount of inventories in the consolidated statement of financial position. | 39.287 | 57.154 | 64.476 | — | 68.075 |
| Trade and bills receivables at period endRMB millionThe prospectus labels this trade and bills receivables; the interim report labels it trade receivables. Values are the net carrying amounts in the statement of financial position. | 2.651 | 19.134 | 40.981 | — | 72.154 |
| Total current liabilities at period endRMB millionTotal current liabilities in the consolidated statement of financial position, not total liabilities. | 70.525 | 127.233 | 130.820 | — | 104.333 |
| Gross margin Calculated%Gross profit / revenue × 100% (site calculation) | 74.3% | 69.6% | 74.1% | 74.1% | 74.2% |
| Attributable profit margin Calculated%Profit attributable to owners of the parent / revenue × 100% (site calculation) | 23.9% | 29.2% | 34.0% | 27.6% | 16.8% |
| R&D expense / revenue Calculated%Absolute expense; Research and development expenses / revenue × 100% (site calculation) | 14.7% | 11.4% | 11.8% | 15.7% | 14.5% |
| Revenue by product category Revenue categories · share of total revenue in brackets | |||||
| Medical implantsRMB million | 186.516(78.2%) | 249.987(76.4%) | 310.375(77.1%) | 99.564(74.1%) | 125.436(76.8%) |
| Surgical equipment and associated medical consumablesRMB million | 51.919(21.8%) | 76.986(23.5%) | 92.020(22.8%) | 34.703(25.8%) | 37.815(23.1%) |
| Other productsRMB million | 0.107(0.0%) | 0.146(0.0%) | 0.356(0.1%) | 0.111(0.1%) | 0.176(0.1%) |
| Revenue by customer location Revenue categories · share of total revenue in brackets | |||||
| Chinese mainlandRMB million | 231.876(97.2%) | 306.267(93.6%) | 332.485(82.6%) | 110.528(82.3%) | 122.729(75.1%) |
| Other countries/regionsRMB million | 6.666(2.8%) | 20.852(6.4%) | 70.266(17.4%) | 23.850(17.7%) | 40.698(24.9%) |
04 / ORIGINAL DISCLOSURES
Sources & reporting basis
These figures are a reference to the original disclosures. Refer to the original documents, definitions and subsequent announcements when using the data.
- Extracted from published official filings and cross-checked against Chinese and English originals; a data presentation, not a separate audit, forecast or new management guidance.
- Page amounts are in RMB million to three decimal places; JSON/CSV downloads retain the source unit of RMB thousands. Costs and expenses retain their negative signs.
- Annual periods compare only with the preceding year; H1 2026 compares only with H1 2025, a supporting base period, never FY2025. Period-end balances are distinct from period flows.
- YoY=(current/prior comparable period−1)×100%; expense changes compare absolute amounts. Where the base is non-positive or the sign changes, prefer the amount change or an inflow/outflow description. Gross margin=gross profit/revenue; attributable profit margin=attributable profit/revenue; expense ratio=absolute expense/revenue; revenue share=category revenue/total revenue. Ratios are site calculations; display rounding may differ slightly from the report.
- null means the selected source does not present that value for the period, not zero. H1 2025 balance-sheet comparatives are not replaced by FY2025 closing balances.
- This version uses the prospectus of 24 April 2026 and interim report published on 18 September 2026. A source publication date is not necessarily the first public availability of each figure. No complete point-in-time history is claimed; corrections should create a new dataset version preserving the prior version and sources.
- Refer to the linked original filings and subsequent corrections for formal disclosures. Printed page numbers and one-based PDF page numbers are supplied for each observation.
- Prospectus dated 24 April 2026
Printed pages I-4, I-5, I-8, I-9, I-24 PDF pages 269, 270, 273, 274, 289
Appendix I historical financial information. The underlying financial statements were audited by Ernst & Young under Hong Kong Standards on Auditing; the accountants’ report was prepared under HKSIR 200.
- 2026 Interim Report
Printed pages 29, 30, 31, 33, 34, 39 PDF pages 30, 31, 32, 34, 35, 40
The 2026 interim financial information is unaudited and reviewed by Ernst & Young under HKSRE 2410. H1 2025 figures are labelled unaudited comparatives and are not described as audited.